Sort   by:  
 Page size 
UnknownEfficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Not available
S-EPMC4872317 | biostudies-literature
UnknownQuantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.
Not available
S-EPMC10495436 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
UnknownT cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.
Not available
S-EPMC12065855 | biostudies-literature
UnknownCharacterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.
Not available
S-EPMC8285118 | biostudies-literature
UnknownDevelopment and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study.
Not available
S-EPMC7832571 | biostudies-literature
UnknownImplementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.
Not available
S-EPMC8940185 | biostudies-literature
UnknownImportance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England.
Not available
S-EPMC8188158 | biostudies-literature
UnknownThe P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Not available
S-EPMC10009825 | biostudies-literature
UnknownPara-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Not available
S-EPMC10746705 | biostudies-literature
Sort   by:  
 Page size